AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05209711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Femoral nerve blockade under ultrasound control without a peripheral nerve stimulator 7.5 ml 1% lidocaine
Description: Under ultrasound visualization guidance, the needle owas positioned at the femoral nerve (in plane) from its lateral side at a slightly superior position . A marker for LA introduction was the visualization of the needle end near the nerve. Subsequently, the introduction of LA solution was initiated. The position of the needle was corrected 1-2 times according to the type of anesthetic spread. If LA was spreading from the lateral side down to the nerve, then the needle was replaced to the upper point of the nerve and the rest of LA was introduced, and vice versa . The presence of a complete and incomplete spread of LA (7.5 ml 1% lidocaine) along the entire circumference of the nerve was assessed. Correspondingly, if the anesthetic was spreading upwardly, the needle would be downwardly replaced.~In addition, a sciatic nerve block is performed.
Study NCT05818410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic device (Lunaris)
Description: Participants with an amputation will conduct experiments with the prosthetic device
Study NCT05818410 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No prosthetic device
Description: Able-bodied individuals will conduct experiments to enable comparison with the participants with amputation
Study NCT05818410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic device (Sach foot)
Description: Participants with an amputation will conduct experiments with the prosthetic device
Study NCT06294483 — intervention group
Intervention type: OTHER
Intervention: 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.
Description: Is criteria of diagnosis of SLE
Study NCT06294483 — intervention group
Intervention type: OTHER
Intervention: SLEDAI scores
Description: Is score to detect the activity of disease
Study NCT05716217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm training
Description: Daily arm training program
Study NCT05724485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain Amino Acid
Description: 12.45 grams of BCAA orally per day before bedtime
Study NCT05724485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12.45 grams of Maltodextrin orally per day before bedtime
Study NCT06452927 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic enucleation of the prostate
Description: Endoscopic enucleation of the prostate, regardless of energy source.~Also see:~* Enucleation is enucleation is enucleation is enucleation~* PMID: 27585786 DOI: 10.1007/s00345-016-1922-3
Study NCT05230615 — intervention group
Intervention type: DRUG
Intervention: Oral semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study NCT04840524 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laminate veneers preparation
Description: facial laminate veneers teeth preparation
Study NCT04840524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laminate veneers preparation
Description: facial laminate veneers teeth preparation
Study NCT05277090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L of polyethyleneglycol
Description: 2L of polyethyleneglycol
Study NCT05277090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inulin
Description: 15g inulin per day
Study NCT05277090 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: probiotic combination product
Description: participants take 2L of polyethyleneglycol, subsequently take 15g probiotics combination product (including Bifidobacterium lactis, Lactobacillus plantarum, inlulin, Vitamin C) per day. The probiotic combination product, named Mei Ri Yi Jun was produced by Wedge Pharmaceuticals.
Study NCT04974086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexually transmitted infection (STI) testing clinical decision support (CDS) tool
Description: The intervention, called the STI Testing CDS tool, includes integrating STI testing guideline prompts into the electronic health record (EHR). The prompt guides clinicians to assess and broadly respond to adolescents' sexual health behaviors through EHR survey data. Through the CDS tool, clinicians will be prompted to provide comprehensive and evidence-based sexual health care for teens including, for example: providing patient-facing education about sexual preventative health topics and facilitating ordering of HIV and sexually transmitted infection (STI) laboratory tests to improve both risk-based and routine annual preventative screening.
Study NCT06099288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Video and Motivational Interviewing Intervention
Description: The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). The CHW will be hired to serve as MI counselors for the parents in the study, and will be in charge of delivering the MI in-home or telephone sessions. CHWs will be trained for 3 months, in Motivational Interviewing, study protocols, the use of video recordings, meal preparation, and cooking, and will undergo a MI certification process. During the sessions with the participants, the CHW will deliver semi-scripted MI sessions based on the scripts developed in the pilot study.
Study NCT06099288 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Read Educate and Develop Youth (READY) Comparison
Description: The comparison group will receive an attention contact control intervention about school readiness promotion adapted from R.E.A.D.Y. (Read Educate and Develop Youth) designed by the Michigan Department of Education. The intervention consists of three home-based visits, followed by phone calls during the last three months of the intervention. For each visit and phone call, participants will receive tailored print materials, and during the 6 months of the interventions, they will receive text messages 2x/week. The intervention will be delivered in English or Spanish by a bilingual Community Health Worker (CHW). Families will receive the same intervention components as the intervention, but about reading instead of nutrition.
Study NCT06072963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: The medication is available in 3, 7, and 14-mg tablets for oral use. Participants will be instructed to start with an initiating dose of 3 mg once daily. If they do not experience adverse events (nausea, vomiting, and abdominal pain) then the dose will be titrated to 7 mg once daily after 30 days. Again, if the participant does not experience adverse events, the dose will be further titrated after 30 days to 14 mg once daily. This does will continue until the end of the study, at 12 months.
Study NCT06072963 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Semaglutide
Description: The medication is available in 3, 7, and 14-mg tablets for oral use. Participants will be instructed to start with an initiating dose of 3 mg once daily. If they do not experience adverse events (nausea, vomiting, and abdominal pain) then the dose will be titrated to 7 mg once daily after 30 days. Again, if the participant does not experience adverse events, the dose will be further titrated after 30 days to 14 mg once daily. This does will continue until the end of the study, at 12 months.
Study NCT06072963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: The study will use the ViaNase; Kurve Technology intranasal device to administer insulin intra-nasally. This device has been used in other studies of persons with AD and has shown insulin penetration into the brain via CSF studies. Through sniffing, the medication crosses the blood-brain barrier (BBB) at the top of the nasal cavity. Participants will be instructed to press a switch that will turn on the device, engaging a pump that releases a nebulized stream of insulin through a nose piece into a nostril for 20 seconds (the device includes an electronic timer), after which the device switches off. The process is then repeated in the other nostril. The investigators decided on administration of 20IU of INI twice per day as the literature suggests this as the optimal dosage.
Study NCT06072963 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intranasal insulin
Description: The study will use the ViaNase; Kurve Technology intranasal device to administer insulin intra-nasally. This device has been used in other studies of persons with AD and has shown insulin penetration into the brain via CSF studies. Through sniffing, the medication crosses the blood-brain barrier (BBB) at the top of the nasal cavity. Participants will be instructed to press a switch that will turn on the device, engaging a pump that releases a nebulized stream of insulin through a nose piece into a nostril for 20 seconds (the device includes an electronic timer), after which the device switches off. The process is then repeated in the other nostril. The investigators decided on administration of 20IU of INI twice per day as the literature suggests this as the optimal dosage.
Study NCT06072963 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Semaglutide placebo
Description: Rybelsus semaglutide - this medicine will simulate taking the pill Rybelsus /semaglutide once a day. A pill identical to the medicine pill will be given.
Study NCT06072963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide placebo
Description: Rybelsus semaglutide - this medicine will simulate taking the pill Rybelsus /semaglutide once a day. A pill identical to the medicine pill will be given.
Study NCT06072963 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intranasal insulin placebo
Description: The placebo used in this study is saline. The investigators will administer saline, with exactly the same methods as the INI insulin (twice per day, 20 seconds each sniff, in each nostril.
Study NCT06072963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal insulin placebo
Description: The placebo used in this study is saline. The investigators will administer saline, with exactly the same methods as the INI insulin (twice per day, 20 seconds each sniff, in each nostril.
Study NCT06089486 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ICA
Description: Patients will undergo annual CAV surveillance with ICA
Study NCT06089486 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET
Description: Patients will undergo annual CAV surveillance with PET
Study NCT05662683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: Virtual reality glasses to be used in the research are not a medical device. This device is a technological glasses that works with compatible smartphones. During the PAP-SMEAR application to be made with this device, watching a nature video with VR is within the framework of midwifery care applications and is not a treatment option for any treatment method, agent or disease. Although the video watched with VR has no effect on medical treatment and care within the framework of midwifery care, it does not have any harmful effects on women. The participant can withdraw from this study at any time without giving any reason.
Study NCT05662683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction Cards Practice Group
Description: It will take about 3-5 minutes to show the cards. The selection of the cards to be used is based on the cards suggested in the literature.
Study NCT05662683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) Breathing Exercise Group
Description: From the preparation stage of the PAP-SMEAR ALDIRAN procedure to the completion of the application process that takes PAP-SMEAR, the virtual reality glasses for breathing exercise by clicking the youtube.com link (https://www.youtube.com/watch?v=Pddb09FAs68) after providing an internet connection with a smartphone for the image. will be provided.
Study NCT06299956 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supervised exercise therapy
Description: Walking on a treadmill at increasing elevation and pace.
Study NCT05171361 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreaticogastrostomy versus Pancreaticojejunostomy with Dunking Technique
Description: To compare between the outcomes of pancreaticogastrostomy and pancreaticojejunostomy with dunking technique after Pancreaticodudenectomy
Study NCT04627441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulator
Description: DS8R Electrical Stimulator For Human Research
Study NCT04627441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural spinal cord stimulator system
Description: Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
Study NCT04827186 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spleen Transplantation/Removal
Description: Spleen transplantation/removal and kidney transplantation alone or simultaneous kidney and pancreas transplantation in highly sensitized patients with either a positive flow cytometry cross-match (FCXM) (T or B cell positive) or a complement-dependent cytotoxicity (CDC) cross-match (B cell positive).
Study NCT05463835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RubusElite
Description: Each 500ml serving of this beverage will contain approximately 30g of milk protein alongside 750mg of polyphenols derived from blackberry puree. The study participant will consume 2 x 500ml per day which will contribute 60g protein and 1500mg polyphenols. No adverse effects associated with the consumption of dairy protein or berry fruits at the proposed intake levels have been reported to date.
Study NCT05463835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 'Protein rich' dairy beverage
Description: This dairy beverage will contain approximately 30g of milk protein /500ml serving and will not contain polyphenols.
Study NCT05463835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: 'Low Protein' dairy beverage
Description: This product also contains no polyphenols and negligible protein.
Study NCT05694936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Description: Sodium valproate oral continuously in a twice daily dose (Initial dose of 600mg/d up-titrated to target daily dose of 20 mg/kg/d at Cycle 1 Day 13, then dose adjusted to maintain serum VPA levels within the target range of 50-100 μg/mL); Refer to arm description.
Study NCT05694936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
Study NCT05694936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
Study NCT05694936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
Study NCT05694936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Panitumumab 6 mg/kg IV every 2 weeks or cetuximab 500 mg/m2 IV every 2 weeks; Refer to arm description.
Study NCT05168514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Patient Identification Form, Pittsburgh Sleep Quality Index and McGill Pain Scale Short Form will be applied to patients with written and verbal consent. Scales and massage application will be done before the pharmacological agent is administered to the patients.~Back massage will be applied to the experimental group for 10 minutes every day for 10 days. Routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the experimental group before and after each massage and scores will be recorded for 10 days.~The control group will not be interfered with, and the routine treatment and care practices in the clinic will continue. Pittsburgh Sleep Quality Index, McGill Pain Scale Short Form will be applied to the control group simultaneously with the experimental group and scores will be recorded for 10 days.
Study NCT06329271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early-Weight bearing
Description: The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
Study NCT06406868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Cancer Society
Description: After taking base line readings the patients will be divided into two groups' experimental group and control group by randomization. The experimental group will receive tele rehabilitation and the control group will receive outpatient rehabilitation. Readings will be taken at the end of every week. The treatment plan of both groups will be the same according to the exercise plan given by American Cancer Society guidelines for breast cancer patients. The exercise plan will start on third day of surgery. A pictorial reference will be given to every patient to perform exercise.~The exercise session will be thrice a week, for 60 min, and for four consecutive weeks, for 12 sessions. Exercise plan consists of three phases:~warm up, balance exercise ,cool down
Study NCT06406868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Cancer Society
Description: After taking base line readings the patients will be divided into two groups' experimental group and control group by randomization. The experimental group will receive tele rehabilitation and the control group will receive outpatient rehabilitation. Readings will be taken at the end of every week. The treatment plan of both groups will be the same according to the exercise plan given by American Cancer Society guidelines for breast cancer patients. The exercise plan will start on third day of surgery. A pictorial reference will be given to every patient to perform exercise.~The exercise session will be thrice a week, for 60 min, and for four consecutive weeks, for 12 sessions. Exercise plan consists of three phases:~warm up, balance exercise ,cool down
Study NCT05241054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: With patient in supine position, the patient will be placed on the operating table with a head-up tilt to reduce venous congestion at the operative site. Skin will be disinfected, the patient will receive local anesthesia by paranasal infiltration at the incision site with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine.
Study NCT05241054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerine
Description: This group includes 32 patients (anticipated), infusion of Nitroglycerine (TNG) (0.2-1µg/kg/min) will be started and adjusted to maintain mean arterial blood pressure between 55-65mmHg.
Study NCT05241054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia will be induced using IV propofol at dose of 1-2 mg.kg
Study NCT05241054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl 1 microgram.kg
Study NCT05241054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium Besylate
Description: Atracurium besylate 0.5mg.kg to facilitate intubation followed will top up dose of atracurium(0.1mg/kg).
Study NCT05241054 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: Patient will then be mechanically ventilated using a volume control mode with tidal volume 6-8ml/kg, respiratory rate 10-14 breath/min and I.E ratio1:2 to maintain end tidal CO2 around 35 mmHg
Study NCT05241054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia will then be maintained using sevoflurane 2%, and 60% air in oxygen mixture and top up dose of
Study NCT04800614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitravatinib
Description: 100 mg sitravatinib on Day 1 of each of 3 periods
Study NCT06098144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm C-Q Gum
Description: Participants will receive a 6-week supply of nicotine replacement treatment (NRT). Based on participants' self-report on the number of cigarettes smoked, these are the possible dosages of NRT gum (2 mg and 4 mg). Participants should not smoke and use the nicotine gum at the same time. Nicotine gum should only be used when cravings for cigarettes arise and should not be treated like regular chewing gum. It is not to be constantly chewed~NRT will be distributed based on the treatment condition.
Study NCT06098144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Quit-line
Description: The TQL is free, and the TQL counselor will provide three phone counseling sessions lasting approximately 15 minutes to devise a specific plan to quit smoking and arrange the delivery of 4 to 12 weeks of NRT based on need. Participants will be advised to request nicotine gums instead of patches to accommodate their job circumstances.